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Available online 19 September 2017Aims: Fabry disease (FD) is a rare X-linked lysosomal storage disease with a deﬁciency of α-galactosidase A
leading to progressive sphingolipid accumulation in different organs, among them heart and kidney. We evaluated
the impact of cardio-renal syndrome (CRS) on the incidence of major cardiovascular complications and death in a
prospective FD cohort.
Methods and results:A total of 104 genetically proven FD patientswere annually followed at the University Hospitals
Zurich and Bern. The main outcome was a composite of incident renal replacement therapy (RRT), hospitalisation
due to decompensated Heart Failure, new onset atrial ﬁbrillation, pacemaker/ICD implantation, stroke/TIA and
death. Estimated glomerular ﬁltration rate (eGFR) and left ventricular myocardial mass index (LVMMI) where ex-
plored as the primary exposure variables. During the median follow-up of 103 [59–155] months, events occurred
in 27 patients. In a Cox regression analysis, both higher LVMMI and lower eGFR were independently associated
with a greater risk of developing adverse events after adjustment for multiple confounders (HR 1.67 [1.04–
2.73] P = 0.03 per SD increase in LVMMI, HR 0.45 [0.25–0.83], P = 0.01 per SD decrease in eGFR). In patients
with CRS, the risk to develop events was signiﬁcantly increased if adjusted for demographics and RRT (HR 4.46
[1.07–18.62], P = 0.04), approaching signiﬁcance if additionally adjusted for hypertension (HR 4.05 [0.95–17.29],
P = 0.06). In Kaplan-Meier-Analysis, the poorest event-free survival was observed among patients with CRS.
Conclusions: CRS was associated with a high risk to develop cardiovascular complications and death, emphasizing
the importance of its prevention and early recognition. A focus on cardio-reno-protective therapies is crucial.
© 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Fabry disease
Cardio-renal syndrome
Risk factors1. Introduction
Fabry disease (FD) is an X-linked lysosomal storage disorder in
which mutations of the GLA gene cause a decreased or absent activity
of the enzymealpha-galactosidase A (α-Gal A) and subsequent progres-
sive intracellular accumulation of globotriaosylceramide (Gb3) and
other sphingolipids in various tissues [1,2]. The initial classic signs and
symptoms include acroparesthesias, angiokeratoma, abdominal pain,
hypohidrosis, corneal dystrophy and typically appear in childhood.
With advancing age, vital organ dysfunction increasingly occurs
resulting in cardiovascular disease, renal failure and premature strokes,
on average more severely in males [3]. Combined renal and cardiacMedicine, University Hospital
land Ltd. This is an open access articldysfunction is common in FD and associated with an increased mortality
and morbidity risk [4,5].
Cardio-renal syndrome (CRS) is an increasingly recognized clinical en-
tity which refers to the reciprocal association between cardiac and renal
dysfunction, whereby injury to one organ directly promotes deterioration
of the other [6]. This complex bilateral organ crosstalk can result from a
variety of conditions where the primary failing organ may be the heart,
the kidney or both. The latter is deﬁned as CRS Type 5 and occurs second-
arily to an underlying systemic process. FD is a typical example of the CRS
Type 5, as described very recently [7]. CRS has been related to a particular-
ly high morbidity and mortality in several settings [6,8,9], however, little
is known about its impact on adverse long-term outcomes in FD patients.
In patients with FD, the indexed left ventricular myocardial mass
(LVMMI) has repeatedly been shown to be a reliable parameter
reﬂecting the onset and progression of Fabry disease-related cardiomy-
opathy [10,11]. The estimated glomerular ﬁltration rate (eGFR) hase under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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risk factor for cardiovascular complications in FD [5]. The aim of this
study was to assess the impact of CRS, reﬂected by LVMMI and eGFR,
on clinical outcomes in a large prospective multicentre cohort of genet-
ically conﬁrmed FDpatients and a long-term follow-up. The recognition
of CRS should lead to speciﬁc prevention strategies and therapeutic
approaches in order to at least attenuate the organ failure in those
patients.
2. Methods
This is a retrospective analysis of a prospective, multi-centre cohort in Switzerland.
The study was conducted in accordance with the principles of the Helsinki Declaration.
The patients who could be contacted gave written informed consent. The authors have
read and approved the manuscript.
2.1. Study population and treatment
The prospective FD cohort consisted of 104 patients, whowere genetically tested (for
further information see the Supplementary Table 1). The cohort was established in 2001
when enzyme replacement therapy (ERT) was newly developed and offered to all FD
patients. Consecutive FDpatientswere registered and received routine annualmultidisciplin-
ary examinations at two tertiary care hospitals – University Hospitals Zürich (93 patients)
and Bern (11 patients). Here, we report on the clinical course and adverse outcomes of
64 females and 40 males.
The baseline clinical evaluationwas performed at the time the patients were included
in the cohort. For the present analysis, the clinical data and information on hospitalisation
were extracted from medical records.
FD patients in Switzerland are personally followed-up and examined at the Fabry
Centres, the adverse events were evaluated during annual examinations. All patients had
a comprehensive workup, including medical history, cardiac evaluation with echocardiog-
raphy, renal, and neurological evaluations. A 24- or 48-hours ECG was performed annually
and additionally if patients complained of palpitations or chest pain. Hospitalisation was
deﬁned as a hospital stay for at least 24 h. Standard transthoracic 2D-echocardiography
was routinely performed in all patients.
For the evaluation of diastolic dysfunction, the left atrial volume index (LAVI), the
mitral inﬂow (E/A ratio) and the mitral annular movement with tissue Doppler (e′ septal
and lateral aswell as an average of E/e′ ratio)wasmeasured according to the current prac-
tice guidelines [12,13]. Thesemeasurementswere performedusing continuous recordings
of mitral inﬂow, analysing the pulsed-wave during 10 s: the peak E-wave velocity (cm/s)
in early diastole, the A-wave (cm/s) in late diastole at the leading edge of the spectral
waveform and the pulsed wave tissue Doppler e′ velocity (cm/s) in early diastole. These
measurements were available in the Zurich subgroup (N = 82) of patients. Diastolic
dysfunction has been graded according to the recent algorithm from the ASE/EACVI
recommendations for the evaluation of the left ventricular diastolic function [13] by
reviewing and repeating all measurements of the archived echocardiographic studies.
Enzyme replacement therapy was initiated according to the written local guidelines
and prescribed at the licensed dose of either 0.2 mg/kg body weight of recombinant
α-agalsidase (Replagal) or 1 mg/kg body weight β-agalsidase (Fabrazyme) and given
intravenously every 14 days. According to the guidelines, ERT was indicated in all males.
In females, ERT was indicated if they had proteinuria of N300 mg per day, Fabry-typical
kidney biopsy ﬁndings, signs of Fabry cardiomyopathy such as left ventricular hypertro-
phy or arrhythmia, stroke or transient ischemic attack (TIA), acroparesthesias despite
conventional analgesic therapy, and/or gastrointestinal symptoms.
2.2. Endpoint deﬁnition and evaluation
As a primary endpoint, we deﬁned the composite of requiring renal replacement
therapy (RRT) (kidney transplantation or chronic dialysis), newly diagnosed atrial ﬁbrilla-
tion (AF) of any type (paroxysmal/persistent), pacemaker and/or ICD implantation,
hospitalisation due to decompensated heart hailure (HF), cerebrovascular events (stroke
or TIA), and death, whichever occurred ﬁrst. The follow-up was censored at the date of
the ﬁrst event to calculate Hazard Ratios. The follow-up time for patients without events
was censored at the 1st of July 2015. If the patients died outside of the Fabry Centre, the
date of death was evaluated by asking the responsible General Practitioner, the family or
the nurse administering ERT in the home care setting.
2.3. Primary exposure variables: cardiac and renal involvement
LVMMI at baseline was used as the primary exposure variable to express cardiac in-
volvement. For this, standard transthoracic 2Dechocardiographywas routinely performed
in all patients. Left ventricular end-diastolic dimension and end-diastolic thickness of the
posterior wall and the septumweremeasured using standardM-mode echocardiographic
methods in parasternal long-axis images. LVMMI was calculated using the Devereux
formula [14].
Estimated glomerular ﬁltration rate (eGFR) at baselinewas used as the primary expo-
sure variable to express renal involvement. The eGFR was derived from serum creatinine
and age using the Chronic KidneyDisease Epidemiology Collaboration (CKD-EPI) [15]. TheCKD-EPI equation is known to have a similarly good statistical performance as previously
used equations when the estimated GFR is below 60 ml/min/1.73 m2, but with better
performance in those with higher eGFR levels [16].
2.4. Statistical analysis
Weused descriptive statistics for the baseline characteristics and laboratory parameters.
Categorical variables were expressed as proportions, continuous variables as means with
standard deviations and medians with interquartile ranges (IQR). Normal distribution was
assessed by the Kolmogorov-Smirnov-Test.
The cut-off values for LVMMI and eGFRwere calculated bymaximizing the product of
sensitivity and speciﬁcity by using receiver operating curve characteristics (ROCs).
Kaplan-Meier analysis was performed for event-free survival and log-rank values to
assess statistical signiﬁcance.
Cox regression analysis was used to examine the risk of adverse events associated
with baseline LVMMI and eGFR on a continuous scale and for cardiac, renal and cardio-
renal involvement as categorical variables. For the categorization, cardiac involvement
was deﬁned as LVMMI above the best calculated cut-off value of 107 (g/m2), we used
this value for both genders becausemales have a higher LVMMI and a higher risk to devel-
op adverse outcomes due to the hemizygosity; renal involvement was deﬁned as eGFR
below the best calculated cut-off value of 90 ml/min/1.73 m2; CRS was deﬁned as
LVMMI N107 (g/m2) and eGFR b90 ml/min/1.73 m2.
Multivariable models were applied to adjust for potential confounders using prior
knowledge of variables that have been associatedwith risk in FD patients in previous studies.
We hierarchically adjusted for demographics (age, gender) in model 1, RRT (kidney
transplant or dialysis at baseline) in model 2 and presence of arterial hypertension (systolic
RR N 140 or diastolic RR N 90 mm Hg or intake of antihypertensive drugs) in model 3.
These models were used for all multivariable Cox regression analyses.
To evaluate the effect of ERT on the primary endpoint, Cox regression analysis was
used, where ERT was expressed as a categorical covariate. In amultivariate Cox regression
analysis, an adjustment for age and gender and for cardio-renal involvement was applied
to evaluate if the ERT effect remained independent.
The statistical analyses were performed using the SPSS/PC (version 22.0; SPSS Inc.,
Chicago, IL, USA) software package. All statistical tests were two-sided, and P values
b0.05 were considered signiﬁcant.
3. Results
The baseline characteristics of all patients according to gender and to
the presence of CRS are shown in Table 1. In total, 104 patients
(40 males and 64 females) with a mean age of 45 ± 16 years were in-
cluded into the analysis. A baseline echocardiography was available in
91, results on diastolic dysfunction in 82 patients. The left ventricular
ejection fraction (LVEF) was normal in all patients. The patients with
cardio-renal involvement at baseline were older, had more frequently
a Classic disease phenotype, arterial hypertension, echocardiographic
signs of diastolic dysfunction, had higher serum NT-proBNP levels and
elevated urine protein/creatinine ratios.
Angiotensin converting enzyme inhibitor (ACE-i) or angiotensin
receptor blocker (ARB) were used in 17 (16%) of the 104 patients at
baseline. During the follow-up time, ACE-i or ARB were started in a
further 17 patients.
The NYHA classes at baseline are summarized in Table 1. At the end
of the follow-up time, NYHA I/II was present in 23 (22%) patients:
7 (18%) males, 16 (25%) females and 10 (23%) in patients with CRS at
baseline; NYHA III/IV was present in 9 (8.6%) patients: 5 (13%) males,
4 (6.3%) females and 5 (12%) patients with CRS at baseline. NYHA
class increased in 24 (23%) patients: 11 (28%) males, 13 (20%) females
and 9 (21%) CRS patients.
48 patients were treated with α-agalsidase and nine with β-
agalsidase throughout the follow-up time. Eight patients were switched
from β-agalsidase to α-agalsidase (seven due to shortage of β-
agalsidase, one at the discretion of the treating physician), one from
α-agalsidase to β-agalsidase (due to patient's priority) an one from
β-agalsidase to α-agalsidase (due to shortage) and back to β-agalsidase
(due to patient's priority).
3.1. Events
During themedian follow-up time of 105 [45–139] months, the ﬁrst
event occurred in 27 (26%) of the patient population: in 11 patients, the
ﬁrst event was stroke or TIA, in 2 kidney transplantation, in 4 chronic
Table 1
Baseline characteristics, laboratory parameters and cumulative ERT dose.
All patients
(n = 104)
Males
(n = 40)
Females
(n = 64)
Patients with cardio-renal involvementa
(n = 29; males n = 14)
Age (years) 45 ± 16 48 ± 14 44 ± 17 60 ± 10
Phenotype
Classic n (%) 89 (86) 33 (83) 56 (88) 28 (97)
Later-onset n (%) 15 (14) 7 (17) 8 (12) 1 (3)
BMI, (kg/m2) 22 (20–25) 22 (19–23) 22 (20–26) 23 (22–25)
ERT n (%)b 65 (63) 35 (88) 31 (48) 25 (86)
Cumulative dose α-agalsidase, (g)c 3.0 (1.4–4.4) 3.4 (2.1–4.6) 2.2 (0.9–3.2) 3.4 (1.9–4.5)
Cumulative dose β-agalsidase, (g)c 13.2 (5.1–19.3) 13.2 (6.5–21.8) 10.6 (4.2–16.9) 17.7 (10.2–20.6)
Mainz Severity Score Index 15 ± 11 21 ± 11 11 ± 8 25 ± 10
Systolic BP (mm Hg) 120 (110−131) 124 (115–133) 120 (110−130) 129 (120–138)
Diastolic BP (mm Hg) 80 (70–82) 80 (75–85) 78 (70–80) 80 (73–90)
Arterial hypertension n (%) 27 (26) 15 (38) 12 (19) 16 (55)
On ACE-i/ARB (%) 17 (16) 12 (30) 5 (8) 9 (31)
Diabetes mellitus n (%) 1 (1) 0 1 (2) 0
Cholesterol (mmol/l) 4.6 (4.1–5.6) 4.3 (3.9–5.4) 4.9 (4.2–5.7) 5.2 (4.3–6.1)
Smoker n (%) 37 (36) 21 (53) 16 (25) 12 (41)
NYHA I/II n (%) 13 (13) 5 (13) 8 (13) 9 (21)
NYHA III/IV n (%) 5 (4.8) 1 (2.5) 4 (6.3) 3 (7)
NT-proBNP, ng/l 435 ± 1222 683 ± 1938 305 ± 614 1083 ± 2131
Creatinine (μmol/l) 75 (67–91) 93 (82–132) 71 (64–76) 94 (75–131)
Protein/creatinine-ratio in urine (m g/mmol) 9 (6–24) 13 (7–39) 8 (4–17) 18 (9–42)
Chronic dialysisd n (%) 7 (7) 7 (18) 0 3 (10)
Renal transplantation n (%) 8 (8) 8 (20) 0 4 (14)
LVMMI (g/m2) 89 (64–127) 109 (80–147) 75 (58–116) 147 (124–190)
LAVI (ml/m2) 28 ± 11 30 ± 13 27 ± 10 39 ± 11
E/e (cm/s) 8 ± 6 8 ± 3 8 ± 7 12 ± 8
Ejection fraction, % 65 ± 7 65 ± 7 64 ± 6 66 ± 7
Atrial ﬁbrillation n (%) 1 (1) 1 (2.5) 0 (0) 0 (0)
Pacemaker 1 (1) 0 (0) 1 (1.6) 0 (0)
Abbreviations: ACE-i= angiotensin converting enzyme inhibitor; ARB= angiotensin receptor blocker; BMI= bodymass index; BP= blood pressure ERT= enzyme-replacement therapy;
HR= Hazard Ratio;; LVMMI = left ventricular myocardial mass index, NYHA New York Heart Association functional class; TIA = transient ischemic attack.
Data are given as mean ± standard deviation, median (interquartile range) or numbers (%).
a Patients with concurrent cardiac (LVMMI N 107 g/m2) and renal (eGFR b 90 ml/min/1.73 m2) involvement at baseline.
b Four males were untreated due to mild phenotype, one due to compliance issue.
c Only patients on ERT included in this analysis.
d At baseline or before kidney transplantation.
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(56%) of the 27 patients who developed an event during the follow-up
time had cardio-renal involvement at baseline. A pacemaker implanta-
tion or AF did not occur as a ﬁrst event.
Overall, 57 events occurred: 4 patients had a new kidney transplan-
tation, of whom 3 (75%) had cardio-renal involvement at baseline; 4
began chronic dialysis, of whom 3 (75%) had cardio-renal involvement
at baseline; 2 patients were hospitalized due to decompensated HF,
both (100%) with cardio-renal involvement at baseline; 11 had at least
one stroke or TIA, 8 (73%) of whom had cardio-renal involvement at
baseline; 7 had new-onset AF, of whom 6 (86%) had cardio-renal in-
volvement at baseline; 6 underwent pacemaker and/or ICD implantation
(with one appropriate shock secondary to sustained ventricular tachy-
cardia in one patient during the entire follow-up period), all of whom
had cardio-renal involvement at baseline. Of these 6 patients, 3 received
a pacemaker due to symptomatic second- or third-degree atrioventricu-
lar block and one due to sinus dysfunction; 3 had an ICD implanted due
to recurrent sustained and hemodynamically not tolerated ventricular
tachycardia. 11 patients died: 2 due to cardiac arrhythmia, 2malignancy,
1 infection, 1 suicide, 5 unknown; 6 (55%) of the deceased had cardio-
renal involvement at baseline. The two male patients (59 and 47 years
old) who died from cardiac arrhythmia, (one ventricular tachycardia
and one asystole with pulseless electrical activity) suffered from cardio-
myopathy, had kidney transplantation and a moderate infection.
The prognostic accuracy of baseline LVMMI and eGFR to predict
major adverse clinical events using ROC curves was moderate to high
as shown in the Supplementary Fig. 1. We calculated an area under the
curve of 0.81 for LVMMI and 0.86 for GFR. The best calculated cut-off
for the events development was 107 g/m2 for LVMMI and 90 ml/min/
1.73 m2 for eGFR.When examining continuous variables using Cox regression anal-
ysis, both higher LVMMI (Table 2A) and lower eGFR (Table 2B) at
baseline were associated with a greater risk of developing an adverse
clinical event in the crude model, after adjustment for possible
confounders in model 1, model 2 and in the fully adjusted model 3.
Of note, LVMMI and eGFR were associated with adverse events inde-
pendently from each other if included into the same fully adjusted
model (Table 2B).
Protein/creatinine ratio in a random urine sample and choles-
terol levels were not associated with the adverse events in the
crude model. These data are not shown. Smoking was associated
with adverse events in the crude Cox regression analysis (HR 2.28
[1.03–5.03], P = 0.04) but lost its independent effect on event
occurrence after adjustment for male gender (HR 2.05 [0.91–4.63],
P = 0.09).
When examining categorical variables in a Cox regression analysis
where (i) cardiac involvement is deﬁned as LVMMI above the best cal-
culated cut-off (N107 g/m2), (ii) renal involvement as eGFR below the
best calculated cut-off (b90 ml/min/1.73 m2) and (iii) CRS as both si-
multaneously, the risk to develop events was higher in patients with
CRS as compared to all patients with cardiac and to all patients with
renal involvement (Table 3) in a crude model. The Cox regression
model for CRS remained signiﬁcant after adjusting for possible
confounders in model 1 and model 2, and approached signiﬁcance in
the fully adjusted model.
The cumulative dose of ERT did not inﬂuence the occurrence of
clinical events for α-agalsidase, β-agalsidase and the sum of both in
patients with cardiac (HR 0.88 [0.68–1.15], P = 0.36 for α-agalsidase;
HR 1.04 [0.97–1.11], P = 0.24 for β-agalsidase; HR 1.04 [0.96–1.12], P =
0.36 for sum), renal (HR 0.89 [0.73–1.08], P = 0.24 for α-agalsidase; HR
Table 2A
Hazard Ratios (and 95% CIs) for occurrence of primary endpointa according to baseline LVMMI.
Parameter Crude Model 1 Model 2 Model 3
HR CI P HR CI P HR CI P HR CI P
LVMMI (g/m2)b 2.14 1.52–3.01 b0.001 1.65 1.06–2.58 0.03 1.67 1.04–2.73 0.03 1.67 1.04–2.73 0.03
Age 1.03 1.00–1.07 0.045 1.03 1.00–1.07 0.06 1.02 0.98–1.06 0.26
Gender 1.56 0.63–3.87 0.34 1.68 0.66–4.32 0.28 1.55 0.60–3.97 0.37
Kidney transplant 0.47 0.07–3.18 0.44 0.42 0.07–2.66 0.36
Dialysis 2.36 0.41–13.68 0.34 2.05 0.11–3.21 0.40
Hypertension 1.92 0.71–5.21 0.20
eGFR 0.32 0.16–0.61 0.001
Abbreviations: LVMMI = left ventricular myocardial mass index; eGFR = estimated glomerular ﬁltration rate; HR = Hazard Ratio; CI = conﬁdence interval.
Model 1: adjusted for age andmale gender; model 2: additionally adjusted for renal replacement - transplantation and dialysis at baseline; model 3: additionally adjusted for presence of
hypertension at baseline.
a Primary endpoint was deﬁned as a composite of ﬁrst occurrence of renal replacement therapy requirement (kidney transplant or chronic dialysis), new onset of atrial ﬁbrillation,
pacemaker and/or ICD implantation, hospitalisation due to decompensated Heart Failure, cerebrovascular events (stroke or TIA), death.
b Per SD decrease.
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for sum) and cardio-renal (HR 0.85 [0.64–1.12], P = 0.24 for
α-agalsidase; HR 1.05 [0.98–1.12], P = 0.20 for β-agalsidase; HR 1.04
[0.87–1.12], P = 0.35 for sum) involvement (all per 1 g increase and in
fully adjusted model).
If deﬁning only RRT, hospitalisation due to decompensated HF,
cerebrovascular events (stroke or TIA), and death as the endpoint
for the Cox regression model, excluding AF as an event of a less clin-
ical severity, higher LVMMI and lower eGFR at baseline remained
associated with a greater risk of developing an adverse clinical
event in the crude model (HR 2.21 [1.43–3.42], P b 0.001 for
LVMMI, HR 0.41 [0.27–0.62], P b 0.001 for eGFR), and remained
signiﬁcant for the eGFR approaching the signiﬁcance for LVMMI
after adjustment for possible confounders in model 1, (HR 1.65
[0.91–2.97], P = 0.10 for LVMMI, HR 0.41 [0.24–0.71], P = 0.001
for eGFR) model 2, (HR 1.74 [0.94–3.20], P = 0.08 for LVMMI, HR
0.37 [0.20–0.70], P = 0.002 for eGFR) and in the fully adjusted model 3
(HR 1.76 [0.98–3.18], P = 0.06 for LVMMI, HR 0.39 [0.20–0.76], P =
0.006 for eGFR) (all models per SD increase in LVMMI and SD
decrease in eGFR).
When examining the effects of ERT on event occurrence, patients on
ERT were at higher risk in the crudemodel (HR 11.62 [1.57–86.05], P =
0.02) and after adjustment for age and gender (HR 9.37 [1.21–72.47],
P = 0.03). However, this “negative” ERT effect was attenuated after
adjustment for cardio-renal involvement at baseline (HR 6.09 [0.76–
49.06], P = 0.09).
In the Kaplan-Meier-Analysis, the poorest event-free survival
was observed among patients with baseline cardio-renal involvement
(Fig. 1, A–C). This effect outweighed the gender-related difference in
outcome within the cohort (Fig. 1, D).
The associations remained unchanged if patients with themutations
c.376ANG/p.S126G and c.416ANG/p.N139S were excluded from the
analysis, due to genetic variants of unknown signiﬁcance.Table 2B
Hazard Ratios (and 95% CIs) for occurrence of primary endpointa according to baseline eGFR.
Parameter Crude Model 1
HR CI P HR CI
eGFRb 0.42 0.28–0.61 b0.001 0.45 0.27–0.74
Age 1.01 0.97–1.04
Gender 1.30 0.56–3.02
Kidney transplant
Dialysis
Hypertension
Abbreviations: LVMMI = left ventricular myocardial mass index; eGFR = estimated glomerula
Model 1: adjusted for age andmale gender; model 2: additionally adjusted for renal replaceme
hypertension at baseline.
a Primary endpoint was deﬁned as a composite of ﬁrst occurrence of renal replacement the
pacemaker and/or ICD implantation, hospitalisation due to decompensated Heart Failure, cere
b Per SD decrease.3.2. Diastolic dysfunction
At baseline, 22 of 82 (27%) patients had a diastolic dysfunction. Of
them, six (27%) showed an abnormal relaxation pattern - corresponding
to diastolic dysfunction grade 1; twelve (55%) pseudonormal ﬁlling
dynamics - grade 2; three (14%) restrictive ﬁlling dynamics – grade 3;
one (4.5%) was inconclusive.
When analysing the parameters of diastolic dysfunction on a contin-
uous scale, E/e` was a signiﬁcant predictor for the occurrence of adverse
clinical events in a crude (HR 1.90 [1.44–2.50], P b 0.001) model and
remained an independent predictor in model 1 (HR 1.63 [1.3–2.35],
P = 0.01), model 2 (HR 1.68 [1.15–2.46], P = 0.007) and model 3
(HR 1.85 [1.23–2.78], P = 0.003]) (per SD increase). In contrast,
LAVI predicted event occurrence in the crude (HR 1.85 [1.33–2.57], P b
0.001) but not in the adjusted models (HR 1.23 [0.80–1.88], P = 0.35
for model 1, HR 1.31 [0.81–2.12], P = 0.27 for model 2 and HR 1.49
[0.89–2.52], P = 0.13 for model 3, (all per SD increase)).
3.3. Hospitalisations
All-cause hospitalisations. Overall, 28 of 104 patients were
hospitalised during the follow-up period: 15 of 29 (52%) patients with
and 13 (17%) of 75 without cardio-renal syndrome at baseline were
ever hospitalised.
From a total of 79 hospitalisations (15 due to cardiac event or
cardiac-related procedure; 8 TIA or stroke, 10 related to RRT, 4 due
to pain, 23 infection, 2 malignancy, 17 other), 57 (72%) occurred in
patients with and 22 (28%) without cardio-renal syndrome at baseline.
3.4. Cardiac hospitalisations
Overall, 9 of 104 patients were hospitalised due to a cardiac event or
procedure. All of these patients had cardio-renal syndrome at baseline.Model 2 Model 3
P HR CI P HR CI P
0.002 0.42 0.24–0.74 0.003 0.45 0.25–0.83 0.01
0.76 1.00 0.97–1.04 0.85 1.00 0.97–1.04 0.98
0.54 1.32 0.51–3.38 0.57 1.23 0.47–3.21 0.67
0.97 0.21–4.59 0.97 1.06 0.23–4.94 0.94
0.75 0.16–3.68 0.73 0.79 0.16–3.78 0.76
1.52 0.58–3.99 0.40
r ﬁltration rate; HR = Hazard Ratio; CI = conﬁdence interval.
nt - transplantation and dialysis at baseline; model 3: additionally adjusted for presence of
rapy requirement (kidney transplant or chronic dialysis), new onset of atrial ﬁbrillation,
brovascular events (stroke or TIA), death.
Table 3
Hazard Ratios (and 95% CIs) for occurrence of primary endpointa according to baseline cardiac, renal and cardio-renal involvement.
Cardiac involvementb (N = 38) Renal involvementc (N = 49) Cardio-renal involvementd (N = 29)
HR 95%CI P HR 95%CI P HR 95%CI P
Crude 4.28 1.58–11.56 0.004 6.38 1.91–21.33 0.003 7.42 2.73–20.23 b0.001
Model 1 1.79 0.55–5.82 0.37 4.30 1.06–17.52 0.04 4.10 1.05–15.99 0.04
Model 2 1.83 0.56–5.97 0.32 4.88 1.12–21.24 0.04 4.46 1.07–18.62 0.04
Model 3 1.75 0.54–5.69 0.35 4.41 0.97–20.06 0.06 4.05 0.95–17.29 0.06
Model 1: adjusted for age andmale gender; model 2: additionally adjusted for renal replacement - transplantation and dialysis at baseline; model 3: additionally adjusted for presence of
hypertension at baseline.
a Primary endpoint was deﬁned as a composite of ﬁrst occurrence of renal replacement therapy requirement (kidney transplant or chronic dialysis), new onset of atrial ﬁbrillation,
pacemaker and/or ICD implantation, hospitalisation due to decompensated Heart Failure, cerebrovascular events (stroke or TIA), death.
b All patients with cardiac (LVMMI N 107 g/m2) involvement at baseline.
c All patients with renal (eGFR b 90 ml/min/1.73 m2) involvement at baseline.
d Patients with concurrent cardiac (LVMMI N 107 g/m2) and renal (eGFR b 90 ml/min/1.73 m2) involvement at baseline.
265M. Siegenthaler et al. / International Journal of Cardiology 249 (2017) 261–267In total, 15 cardiac hospitalisations occurred: 8 due to pacemaker/ICD
implantation and related complications, 2 acute coronary events, 2
aortic valve replacements, 2 decompensated heart failure, 1 arrhythmic
event.
4. Discussion
In this prospective multicentre cohort of 104 Swiss Fabry patients,
CRS was associated with a high risk of complications such as death,
stroke/TIA, hospitalisation due to decompensated HF and requirement
for renal replacement therapy. Cardiac and renal disease independently
increased the risk for major clinical events. Interestingly, cardio-renal
involvement was a more important independent risk factor than male
gender, despite the fact that FD is an X-linked inherited disorder.
Concurrent cardiac and renal involvement may reﬂect an advanced
Gb3 deposition in the vital organs. Indeed, studies have demonstrated
that patients with advanced stages of FD tend to experience disease pro-
gression and beneﬁt less from enzyme replacement therapy [17,18].
Moreover, cardio-renal involvement was often associated with the more
severe classic FD phenotype; in contrast, single-organ manifestationsFig. 1. Time to ﬁrst complication in Fabry patients presented in groups using the best calculat
(C) and according to gender (D).seemed to correspond to the later-onset phenotype, which is known for
a milder vascular risk proﬁle [19]. Furthermore, renal disease itself has
been shown to be a major risk factor for cardiovascular complications in
FD [5]. Similarly, left ventricular hypertrophy was a signiﬁcant predictor
for cardiovascular events in a large-scale registry-based long-term study
[20].
Additional pathophysiological mechanisms beyond glycosphingolipid
deposition have been proposed to enhance the cardio-renal problem in
patients with Fabry disease. On the cellular level, the lysosomal dys-
function may trigger a damaging cascade of events such as cell apopto-
sis, energy depletion [21], increased oxidative stress [22], inﬂammation
[23] and ﬁnally cardiac [24,25] and renal tissue ﬁbrosis [26,27]. On the
organ level, left ventricular hypertrophy, diastolic dysfunction and ar-
rhythmia can lead to a reduced cardiac output and a consecutive arterial
underﬁlling resulting in reduced renal perfusion aswell as renal venous
congestion. On the other hand, reduced glomerular ﬁltration rate causes
salt and water retention, azotemia and acid base imbalance, further
increasing the cardiac preload and predisposing to left ventricular and
diastolic dysfunction. These haemodynamic derangements likely result
in an activation of the renin-angiotensin-aldosterone-system and aed cut-offs for LVMMI and eGFR at baseline (A), eGFR at baseline (B), LVMMI at baseline
266 M. Siegenthaler et al. / International Journal of Cardiology 249 (2017) 261–267release of vasoactive mediators responsible for systemic vasoconstric-
tion. Along the same lines, arterial hypertension has repeatedly been
shown as an important risk factor in Fabry disease progression [20].
As shown in this study, diastolic dysfunction plays an important
prognostic role in FD. Diastolic dysfunction is known to be an early
sign of cardiac involvement in FD occurring before LVH28. Our results
are in line with a study by Boyd et al., in which left atrial enlargement
and reduced atrial compliance in particular were shown as crucial
early signs of Fabry cardiomyopathy [28]. This left atrial enlargement
as a result of chronic left atrial pressure elevation may lead to renal
venous congestion, initiating the vicious cycle of CRS.
Cardiac and renal deterioration should consequently be prevented
as far as possible in order to reduce morbidity and mortality. Within
our cohort, patients on ERT were still at an increased risk of developing
adverse clinical events, which continued to occur independently of the
cumulative ERT dose, even after adjustment for possible confounders.
The most likely reason for this observation is that ERT was indicated
in patients with more severe phenotypes and was initiated relatively
late. Importantly, we studied an “old” FD population where a large pro-
portion of the patients had advanced disease, ERT having been initiated
and offered to all FD patients from 2001. In this cohort, a high propor-
tion of females (48%) was on ERT but could have been at lower risk of
having major clinical events due to the heterozygosity. Therefore, in
order to avoid bias by gender, adjustment for gender as a possible
confounder has been introduced already in Model 1 and maintained in
all multivariate models.
Of note in this study, we adopted a deﬁnition of CRS leading to a
focus on patients with relatively “advanced “disease. Importantly, we
studied an “older” adult FD population where a large proportion of the
patients had advanced disease at baseline, because the cohort was
established when ERT was initiated and offered to all FD patients in
2001. In the future, it is important to study the association of early
disease involvement with clinical events because early ERT initiation
beneﬁts the clinical long-term outcome [17,29].
Because Gb3 accumulation is known to occur at early stages of Fabry
nephropathy [30,31] and cardiomyopathy [32], early initiation of en-
zyme replacement therapy prior to overt kidney and heart disease
may lead to prevention of CRS. Studies suggest that maximal treatment
effect can be achieved at early stages of heart and kidney involvement
[33,34].
To slow disease progression, more intensive therapies such as in-
creased ERT dose or additional pharmacological chaperone therapy
could enhance the therapeutic outcomes [35–37]. Fabry patients with
advanced cardio-renal disease might additionally beneﬁt from general
therapies used to control cardiac and renal disease by RAAS inhibition
using angiotensin-converting enzyme inhibitors or angiotensin blockers
in the chronic and diuretic therapy in the acute setting. Patients with
advanced disease should undergo a routine organ staging at regular in-
tervals [38] and be treated according to current guidelines [39].
We included ﬁve patients with mutations c.376ANG/p.S126G and
c.416ANG/p.N139S, reported in literature as genetic variants of
unknown signiﬁcance [40–43]. Three males, 55, 45 and 23 year old,
and one female, 53 year old, with the mutation c.376ANG/p.S126G,
had no cardiac or renal involvement at baseline and at 4 years follow-
up, which conﬁrms a rather benign nature of this mutation. Similarly,
the 43 year old female with the mutation c.416ANG/p.N139S had
no cardiac or renal involvement at baseline and at 2 years follow-up.
Importantly, the associations with the clinical outcomes remained
unchanged if patients with these mutations were excluded from the
analysis.”
Several limitations merit consideration. Firstly, due to a relatively
small cohort size, we had to deﬁne a composite outcome in order to in-
crease the power of this study. Secondly, cardiac MRI was not available
at cohort initiation. Thirdly, we cannot conclude from this study towhat
extent patients with cardio-renal involvement beneﬁted from enzyme
replacement therapy.The strengths of this study are its long observational period for hard
clinical outcomes in a multicentre cohort in a single country, where
patients are treated similarly and exposed to similar environmental
conditions, and its negligible loss to follow-up. The latter is due to
Swiss regulation that the ERT prescription and patient's follow-up
remains reserved for the Fabry Centres.
In conclusion, cardio-renal involvement in Fabry disease is a poten-
tial marker of disease progression bearing an increased risk of mortality
and cardiovascular events. Multidisciplinary care provided by cardiolo-
gists, nephrologists, general physicians and other specialists is impor-
tant in treating the Type 5 cardio-renal syndrome seen in Fabry disease.
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